Alaunos Therapeutics, Inc. (TCRT)Healthcare | Biotechnology | Fort Lauderdale, United States | NasdaqCM
1.61 USD
-0.05
(-3.313%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.61 +0.00 (0.312%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:39 a.m. EDT
The immediate outlook is severely clouded by a relentless multi-year price collapse. Despite a minor recent bounce, the stock has endured six consecutive years of negative annual returns, culminating in a staggering 99.8% loss over the last nine years. This trajectory is not a temporary correction but a structural implosion where the market has repeatedly rejected the business model, evidenced by the drop from a 2016 high of $885 to a current price under $2. Fundamentally, the company is in deep distress with negative earnings, massive operating losses, and a price-to-sales ratio of nearly 1,500x, indicating a complete disconnect between valuation and revenue generation. There is no reliable income stream to offset this capital destruction, making this a clear avoidance for any rational investor. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.296709 |
| AutoETS | 0.296716 |
| AutoTheta | 0.297380 |
| MSTL | 0.307551 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 2.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.001 |
| Market Cap | 4,077,470 |
| Forward P/E | -2.68 |
| Beta | -0.96 |
| Previous Name | ZIOPHARM Oncology, Inc. |
| Website | https://www.alaunos.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2719298 |
| Address1 | 501 E. Las Olas Blvd. |
| Address2 | Suite 300 |
| All Time High | 2,400.0 |
| All Time Low | 1.31 |
| Ask | 1.86 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 14,310 |
| Average Daily Volume3 Month | 14,014 |
| Average Volume | 14,014 |
| Average Volume10Days | 14,310 |
| Beta | -0.96 |
| Bid | 1.33 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 0.542 |
| City | Fort Lauderdale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.605 |
| Current Ratio | 0.771 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.71 |
| Day Low | 1.55 |
| Display Name | Alaunos Therapeutics |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -4,034,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.98 |
| Enterprise To Revenue | 1,317.823 |
| Enterprise Value | 3,953,470 |
| Eps Forward | -0.6 |
| Eps Trailing Twelve Months | -1.75 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9986 |
| Fifty Day Average Change | -0.3936 |
| Fifty Day Average Change Percent | -0.19693784 |
| Fifty Two Week Change Percent | -27.19298 |
| Fifty Two Week High | 4.59 |
| Fifty Two Week High Change | -2.9850001 |
| Fifty Two Week High Change Percent | -0.6503268 |
| Fifty Two Week Low | 1.55 |
| Fifty Two Week Low Change | 0.055000067 |
| Fifty Two Week Low Change Percent | 0.035483915 |
| Fifty Two Week Range | 1.55 - 4.59 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,124,890,200,000 |
| Float Shares | 1,980,457 |
| Forward Eps | -0.6 |
| Forward P E | -2.675 |
| Free Cashflow | -1,570,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Fullday Change | -0.0549999 |
| Fullday Change Percent | -3.31325 |
| Fullday Price | 1.61 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -1,643,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15296 |
| Held Percent Institutions | 0.04877 |
| Implied Shares Outstanding | 2,540,480 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.ziopharm.com/index.cfm |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,721,260,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida. |
| Long Name | Alaunos Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 4,077,470 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_11686323 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -4,116,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,217,196 |
| Open | 1.66 |
| Operating Cashflow | -2,727,000 |
| Operating Margins | -1,352.3333 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.58 |
| Phone | 346 355 4099 |
| Post Market Change | 0.004999995 |
| Post Market Change Percent | 0.31152618 |
| Post Market Price | 1.61 |
| Post Market Time | 1,787,959,805 |
| Prev Name | ZIOPHARM Oncology, Inc. |
| Previous Close | 1.66 |
| Price Hint | 4 |
| Price To Book | 2.9612546 |
| Price To Sales Trailing12 Months | 1,359.1566 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.144 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.054999948 |
| Regular Market Change Percent | -3.31325 |
| Regular Market Day High | 1.71 |
| Regular Market Day Low | 1.55 |
| Regular Market Day Range | 1.55 - 1.71 |
| Regular Market Open | 1.66 |
| Regular Market Previous Close | 1.66 |
| Regular Market Price | 1.605 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 35,723 |
| Return On Assets | -0.81127 |
| Return On Equity | -1.85949 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 2,540,480 |
| Shares Percent Shares Out | 0.0049 |
| Shares Short | 12,512 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 13,319 |
| Short Name | Alaunos Therapeutics, Inc. |
| Short Percent Of Float | 0.0053 |
| Short Ratio | 1.41 |
| Source Interval | 15 |
| State | FL |
| Symbol | TCRT |
| Total Cash | 124,000 |
| Total Cash Per Share | 0.049 |
| Total Debt | 0 |
| Total Revenue | 3,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.73645 |
| Two Hundred Day Average Change | -1.1314499 |
| Two Hundred Day Average Change Percent | -0.41347364 |
| Type Disp | Equity |
| Volume | 35,723 |
| Website | https://www.alaunos.com |
| Zip | 33,301 |